RxDoctor Payments Data

Rafat Padaria, MD

Cardiovascular Disease · Davenport, IANPI 1497734388

Payments from drug & device makers

$1,618in general payments, 2019–2025

Across 31 payments — averaging $52.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$154
  • Johnson & Johnson$121
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$68
  • Tactile Systems Technology Inc$67
  • Boston Scientific$40
  • plus $70 from 4 others

What the payments were for

  • Consulting fees$32520%
  • Food & beverage$1,29380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,618 in reported general payments places this provider in the 50th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$958,895
Medicare patients
1,495
Services billed
4,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban414$468,073
XareltoRivaroxaban135$168,535
EntrestoSacubitril/Valsartan112$137,202
JardianceEmpagliflozin110$116,490
BrilintaTicagrelor35$28,010
Ranolazine ErRanolazine110$15,357
Dabigatran EtexilateDabigatran Etexilate Mesylate55$11,403
Metoprolol Succinate599$6,825
Fenofibrate95$5,324
Atorvastatin Calcium598$5,057
Potassium Chloride209$3,905
ClopidogrelClopidogrel Bisulfate328$3,828
Diltiazem 24hr Er (Cd)Diltiazem Hcl121$3,653
Ezetimibe151$2,745
Metoprolol Tartrate590$2,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$121$168,535135 claims
NovartisEntresto$11$137,202112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →